title: Circulating sRAGE in the diagnosis of osteolytic bone metastasis.
abstract: Despite the clinical importance of metastasis to the skeleton, the diagnostic tools for early detection and monitoring of bone metastasis lack sensitivity and specificity. We evaluated a promising new serum biomarker, the soluble form of the Receptor of Advanced Glycosylated End-products (sRAGE). sRAGE is involved in the Wnt-signaling pathway, and has been reported to reduce the risk of cancer. We investigated the diagnostic potential of sRAGE to improve the detection and monitoring of bone metastasis. We measured sRAGE in the serum of control healthy subjects, patients with primary tumors and patients with bone metastasis. sRAGE was also correlated with the Wnt inhibitors DKK-1 and sclerostin, the bone resorption markers MMP-2, MMP-9 and TRAP5, and the metastatic marker survivin. sRAGE was significantly lower in primary tumor and metastatic patients than in healthy subjects. sRAGE also showed a strong negative correlation with DKK-1, sclerostin, MMP-2, MMP-9, TRAP5b and survivin. These results indicated that sRAGE might play a protective role in bone metastasis progression, and it may diagnostic significance for detecting and monitoring osteolytic metastases.
authors.affiliation: Department of Biomedical, Surgical and Oral Science, Università degli Studi di Milano, Milan, Italy.|IRCCS Galeazzi Orthopedic Institute, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Galliera
authors.affiliation: Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
authors.forename: M G
authors.initials: MG
authors.lastname: Marazzi
authors.affiliation: Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Vianello
authors.affiliation: IRCCS Galeazzi Orthopedic Institute, Milan, Italy.|Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Drago
authors.affiliation: IRCCS Galeazzi Orthopedic Institute, Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Luzzati
authors.affiliation: Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Bendinelli
authors.affiliation: IRCCS Galeazzi Orthopedic Institute, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Maroni
authors.affiliation: Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Tacchini
authors.affiliation: Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.
authors.forename: M A
authors.initials: MA
authors.lastname: Desiderio
authors.affiliation: Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milan, Italy.|U.O.C SMEL-1 Patologia Clinica IRCCS Policlinico San Donato, San Donato, Milan, Italy.
authors.forename: M M
authors.initials: MM
authors.lastname: Corsi Romanelli
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000556:secondary; D005260:Female; D006801:Humans; D007118:Immunoassay; D008297:Male; D010014:Osteolysis / Q000097:blood / Q000175:diagnosis / Q000209:etiology; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood*
chemical_list: C000593871:AGER protein, human; D014408:Biomarkers, Tumor; D000067759:Receptor for Advanced Glycation End Products